Patent strategies in the antisense oligonucleotide based therapeutic approach
- 1 October 1997
- journal article
- Published by Informa Healthcare in Expert Opinion on Therapeutic Patents
- Vol. 7 (10) , 1175-1182
- https://doi.org/10.1517/13543776.7.10.1175
Abstract
Antisense oligonucleotides represent a new approach to therapeuric treatment of a variety of diseases.Due to unique aspects of this new approach, the opportunity to protect inventions via patenting is potentially greater than for small molecule pharmaceutical products.Strategies for protecting antisense technology include developing a multiple layered patent portfolio covering a range of compositions of matter having improved pharmacological properties.Such patentable new compositions of matter arise from exploitation of pharmacological properties discobered in preclinical and clinical trials, and from new synthetic and manufacturing processes, which provide new chemical entities.In addition,advances in manufacturing technology reduce the cost of antisense oligonucleotides and are independently patentable.In this article, the general strategic approach to patenting antisense technology will be presented, together with illustrative examples of the implemantation of such a strategy.For this purpose,primaril...Keywords
This publication has 13 references indexed in Scilit:
- Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: In vitro and in vivo studiesProceedings of the National Academy of Sciences, 1997
- N-pent-4-enoyl (PNT) group as a universal nucleobase protector: Applications in the rapid and facile synthesis of oligonucleotides, analogs, and conjugatesTetrahedron, 1997
- In vivo studies with antisense oligonucleotidesTrends in Pharmacological Sciences, 1997
- Mixed backbone oligonucleotides containing internucleotidic primary phosphoramidate linkagesBioorganic & Medicinal Chemistry Letters, 1996
- N-pent-4-enoyl nucleosides: Application in the synthesis of support-bound and free oligonucleotide analogs by the H-phosphonate approachTetrahedron Letters, 1996
- Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administrationBiochemical Pharmacology, 1995
- Study of antisense oligonucleotide phosphorothioates containing segments of oligodeoxynucleotides and 2′-o- methyloligoribonucleotidesBioorganic & Medicinal Chemistry Letters, 1994
- GEM* 91—An Antisense Oligonucleotide Phosphorothioate as a Therapeutic Agent for AIDSAntisense Research and Development, 1992
- Site-specific excision from RNA by RNase H and mixed-phosphate-backbone oligodeoxynucleotides.Proceedings of the National Academy of Sciences, 1990
- Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide.Proceedings of the National Academy of Sciences, 1978